Related Experiment Video
Updated: Feb 23, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Ganaxolone: A New Treatment for Neonatal Seizures
Tamara Yawno1,2, Suzie L Miller1,2, Laura Bennet3
1Ritchie Centre, Hudson Institute of Medical ResearchClayton, VIC, Australia.
Insights
Ganaxolone, a neurosteroid, shows promise in controlling neonatal seizures and protecting the brain. Early use may prevent long-term disabilities like cerebral palsy and epilepsy.
Area of Science:
- Neonatal neurology
- Neuropharmacology
Background:
- Neonatal seizures are a common neurological issue in newborns.
- Seizures can worsen brain injury and lead to neurodevelopmental problems later in life.
Purpose of the Study:
- To review evidence supporting ganaxolone as a novel neonatal therapy for seizures.
- To evaluate ganaxolone's potential for seizure control and neuroprotection.
Main Methods:
- Review of existing scientific literature on ganaxolone in neonatal contexts.
- Analysis of data regarding ganaxolone's efficacy and safety profile.
Main Results:
- Ganaxolone, a GABAA agonist neurosteroid, demonstrates potential for seizure control.
- Evidence suggests ganaxolone offers neuroprotection with a favorable safety profile when given early after birth-related hypoxia.
Conclusions:
- Ganaxolone may prevent or reduce disabilities such as cerebral palsy and epilepsy.
- Ganaxolone is proposed as an ideal anti-seizure treatment due to its safety and potential benefits in neonates.
Abstract:
Neonatal seizures are amongst the most common neurologic conditions managed by a neonatal care service. Seizures can exacerbate existing brain injury, induce "de novo" injury, and are associated with neurodevelopmental disabilities in post-neonatal life. In this mini-review, we present evidence in support of the use of ganaxolone, a GABAA agonist neurosteroid, as a novel neonatal therapy. We discuss evidence that ganaxolone can provide both seizure control and neuroprotection with a high safety profile when administered early following birth-related hypoxia, and show evidence that it is likely to prevent or reduce the incidence of the enduring disabilities associated with preterm birth, cerebral palsy, and epilepsy. We suggest that ganaxolone is an ideal anti-seizure treatment because it can be safely used prospectively, with minimal or no adverse effects on the neonatal brain.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:13Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:26Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...